Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.33 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 2/20 | 0.31 |
| ▸ | HRH1 | P35367 | 2/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13740262 | 1.00 | KDM1A (0.33) | KDM1ALTA4HGNAI3GNAO1GNAI1 | |
| SCHEMBL22789404 | 1.00 | KDM1A (0.33) | KDM1ALTA4HGNAI3GNAO1GNAI1 | |
| SCHEMBL12245493 | 0.88 | ADORA2A (0.33) | KDM1AADORA2A | |
| SCHEMBL14737759 | 0.88 | ADORA2A (0.33) | KDM1AADORA2A | |
| SCHEMBL459481 | 0.86 | GNAI3 (0.39) | KDM1AGNAI3GNAO1GNAI1 | |
| Hydrochloric Acid SCHEMBL14738232 | 0.86 | ADORA2A (0.32) | KDM1AADORA2A | |
| Hydrochloric Acid SCHEMBL2378908 | 0.86 | ADORA2A (0.32) | KDM1AADORA2A | |
| Hydrochloric Acid SCHEMBL14738192 | 0.86 | ADORA2A (0.32) | KDM1AADORA2A | |
| Hydrochloric Acid SCHEMBL14738190 | 0.86 | ADORA2A (0.32) | KDM1AADORA2A | |
| Hydrochloric Acid SCHEMBL16973697 | 0.84 | GNAI3 (0.42) | KDM1AGNAI3GNAO1GNAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO INC (US) | 2026-03-26 | — | — | US | disclosed |
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085067-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | RRM1, RRM2B, RRM2 | KDM1A 3197/4885LTA4H 4121/4885GNAI3 4157/4885 |
| US-10287301-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of medical disorders | CFD, F12, F3 | KDM1A 4506/4885LTA4H 524/4885GNAI3 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.